Presentation is loading. Please wait.

Presentation is loading. Please wait.

Immunotherapy of NK-92-S3KD increases anticancer effector productions in HepG2-bearing mice. Immunotherapy of NK-92-S3KD increases anticancer effector.

Published byDaniel Gjertsen Modified over 4 years ago

Similar presentations

Presentation on theme: "Immunotherapy of NK-92-S3KD increases anticancer effector productions in HepG2-bearing mice. Immunotherapy of NK-92-S3KD increases anticancer effector."— Presentation transcript:

1 Immunotherapy of NK-92-S3KD increases anticancer effector productions in HepG2-bearing mice.
Immunotherapy of NK-92-S3KD increases anticancer effector productions in HepG2-bearing mice. A–C, Tumor tissue–derived human IFNγ, granzyme B, and perforin. D–F, Serum levels of human IFNγ, granzyme B, and perforin. Results showed that the levels of IFNγ, granzyme B and perforin in both tumor tissues and serum of HepG2-bearing mice on day 28 after tumor inoculation were enhanced in the tumor-bearing mice treated with NK-92-S3KD cells compared with parental cells. Data represent mean ± SME of three independent experiments for groups of at least 6 mice. **, P < 0.01; ***, P < versus the saline group; ###, P < versus the NK-92-EV group. Qing-Ming Wang et al. Cancer Immunol Res 2018;6: ©2018 by American Association for Cancer Research

Download ppt "Immunotherapy of NK-92-S3KD increases anticancer effector productions in HepG2-bearing mice. Immunotherapy of NK-92-S3KD increases anticancer effector."

Similar presentations

Activation of NK cells during the early stage of allergic and fibrotic lung inflammation. Activation of NK cells during the early stage of allergic and.

Activation of NK cells during the early stage of allergic and fibrotic lung inflammation. Activation of NK cells during the early stage of allergic and.
Enhanced ILC2 expansion after depletion of NK cells during the early stage of allergic and fibrotic lung inflammation. Enhanced ILC2 expansion after depletion.

Enhanced ILC2 expansion after depletion of NK cells during the early stage of allergic and fibrotic lung inflammation. Enhanced ILC2 expansion after depletion.
Inhibition of CR HCT-116 (A and B) or CR HT-29 cells (B) xenografts in EPA and/or FuOx-treated SCID mice. Inhibition of CR HCT-116 (A and B) or CR HT-29.

Inhibition of CR HCT-116 (A and B) or CR HT-29 cells (B) xenografts in EPA and/or FuOx-treated SCID mice. Inhibition of CR HCT-116 (A and B) or CR HT-29.
Frequencies of immune cell types show much stronger variations between tumor types in the tumor infiltrate compared with the spleen and tumor-draining.

Frequencies of immune cell types show much stronger variations between tumor types in the tumor infiltrate compared with the spleen and tumor-draining.
Combined A2A receptor and PD-1 blockade is not effective in IFNγ−/− mice. Combined A2A receptor and PD-1 blockade is not effective in IFNγ−/− mice. AT-3ovadim.

Combined A2A receptor and PD-1 blockade is not effective in IFNγ−/− mice. Combined A2A receptor and PD-1 blockade is not effective in IFNγ−/− mice. AT-3ovadim.
H31m1-PDL1 cells form progressively growing tumors in WT mice.

H31m1-PDL1 cells form progressively growing tumors in WT mice.
Tumor development of poorly immunogenic LLC and B16F10 cells modified to produce GM-CSF was markedly inhibited. Tumor development of poorly immunogenic.

Tumor development of poorly immunogenic LLC and B16F10 cells modified to produce GM-CSF was markedly inhibited. Tumor development of poorly immunogenic.
Gr-1+ MDSC in tumor-bearing mice produce IL-6.

Gr-1+ MDSC in tumor-bearing mice produce IL-6.
The absence of ADCC by nivolumab in vitro.

The absence of ADCC by nivolumab in vitro.
Highly related T9 and T3 sarcoma cells show distinct tumor growth patterns but similar PD-L1 expression kinetics in vivo. Highly related T9 and T3 sarcoma.

Highly related T9 and T3 sarcoma cells show distinct tumor growth patterns but similar PD-L1 expression kinetics in vivo. Highly related T9 and T3 sarcoma.
Antitumor effect of local cancer immunotherapy treatment in various tumor models. Antitumor effect of local cancer immunotherapy treatment in various tumor.

Antitumor effect of local cancer immunotherapy treatment in various tumor models. Antitumor effect of local cancer immunotherapy treatment in various tumor.
Mouse lymphoma model. Mouse lymphoma model. A, EL-Arf−/− cells (1 × 106) were tail-vein injected into C57BL/6 mice. LNIWC imaging was separated into 2.

Mouse lymphoma model. Mouse lymphoma model. A, EL-Arf−/− cells (1 × 106) were tail-vein injected into C57BL/6 mice. LNIWC imaging was separated into 2.
Ablation of PD-L1 in edited T3 sarcoma cells leads to augmented growth inhibition in WT mice. Ablation of PD-L1 in edited T3 sarcoma cells leads to augmented.

Ablation of PD-L1 in edited T3 sarcoma cells leads to augmented growth inhibition in WT mice. Ablation of PD-L1 in edited T3 sarcoma cells leads to augmented.
Protection from 4T1 tumor rechallenge in treated mice.

Protection from 4T1 tumor rechallenge in treated mice.
Frequency and kinetics of killer cell apoptosis are dependent on functional conjugations with multiple NALM-6 tumor cells. Frequency and kinetics of killer.

Frequency and kinetics of killer cell apoptosis are dependent on functional conjugations with multiple NALM-6 tumor cells. Frequency and kinetics of killer.
Dox administration was required for Tet-CD19CAR T cells to show a suppressive function against a CD19+ tumor in vivo. Dox administration was required for.

Dox administration was required for Tet-CD19CAR T cells to show a suppressive function against a CD19+ tumor in vivo. Dox administration was required for.
NK Cells Fighting Cancer

NK Cells Fighting Cancer
The contributions of anti-Ad antibody and T-cell responses to viral clearance in tumor and antitumor efficacy of Ad5 therapy. The contributions of anti-Ad.

The contributions of anti-Ad antibody and T-cell responses to viral clearance in tumor and antitumor efficacy of Ad5 therapy. The contributions of anti-Ad.
Mice immunized twice with RRBC showed superior protection to tumor challenge with αGal-positive MC38 colon carcinoma cells compared with mock-immunized.

Mice immunized twice with RRBC showed superior protection to tumor challenge with αGal-positive MC38 colon carcinoma cells compared with mock-immunized.
Adaptive NK cells resist immunosuppression in the tumor microenvironment. Adaptive NK cells resist immunosuppression in the tumor microenvironment. FACS-sorted.

Adaptive NK cells resist immunosuppression in the tumor microenvironment. Adaptive NK cells resist immunosuppression in the tumor microenvironment. FACS-sorted.

Similar presentations

Ads by Google